Ipsen : Valuation vs newsflow: the dilemma – revised target price of € 83.3 vs € 90
>Palovarotene: the electric shock? - Early December, the FDA asked Ipsen to suspend clinical trials on palovarotene (drug acquired from Clementia early 2019) on children under 14due to early growth plate closure in many paediatric patients.This announcement comes nine months after the acquisition of Clementia, one month after head of R&D was replaced and one quarter ahead of the scheduled filing for market authorisation with the FDA. This calls into question...Ipsen is global biotechnology specialty care company. Co. engages in research, development, manufacture and sale of pharmaceutical products for human healthcare. Co.'s product portfolio includes pharmaceutical products marketed around the world to specialists working in its targeted therapeutic areas (oncology, endocrinology, neurology and haematology). These products are specialist care drugs. Co. also markets products in other therapeutic areas including gastroenterology, cardiovascular and cognitive disorders. These products are primary care drugs. Co.'s brand names include Decapeptyl®, Somatuline®, Dysport®, Nutropin Aq®, Smecta®, Forlax®, Nisis®,Adrovance®, Exforge® and Adenuric®.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.